Second interim analysis of the Global Investigation of Therapeutic Decisions in Unresectable HCC (uHCC) and of Its Treatment with Sorafenib (GIDEON): Differences in AE reporting across physician specialties.

Abstract

286 Background: GIDEON is an ongoing, global, prospective, non-interventional study of patients (pts) with uHCC receiving sorafenib (Sor) in real-life practice. Differences in pt management across physician specialties can be explored. Methods: The 2nd interim analysis was pre-planned when ~1500 treated pts were followed for ≥4 months. The predefined descriptive subgroup analysis by specialty is presented. Results: Median days between visits varied across specialties: medical oncologists (Med Oncs) had the shortest. Sor dosing was broadly similar across specialties, with hepatologists/gastroenterologists (Hep/GIs) having the greatest incidence of dose reductions. Most commonly reported (>20% of pts) adverse events (AEs; e.g. diarrhea, hand-foot skin reaction [HFSR], fatigue) were similar across specialties, but the incidences varied. These AEs and grade 3/4 AEs were reported by more Hep/GIs and Med Oncs than by surgeons. The incidences of liver-related AEs varied across specialties. Interval-specific AE rates by specialty will be presented. Conclusions: Interim data from GIDEON highlight variations in the assessment and management of uHCC pts across specialties. The reporting of AEs and dose reductions may reflect the frequency of visits with physicians. Findings support the importance of a multidisciplinary team approach to optimize pt care. [Table: see text]